CD8A and neoplasm: Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, may contribute to this association via immunomodulatory effects including normalizing tumor vasculature and enhancing the infiltration of CD4+ T-cells, CD8+ T-cells, and mature dendritic cells into the tumor microenvironment [18].